{"id":2049,"date":"2023-06-19T11:54:27","date_gmt":"2023-06-19T08:54:27","guid":{"rendered":"https:\/\/integris.gr\/ogkologia-aimatologia\/"},"modified":"2026-01-14T10:58:00","modified_gmt":"2026-01-14T08:58:00","slug":"ogkologia-aimatologia","status":"publish","type":"page","link":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/","title":{"rendered":"Oncology – Haematology"},"content":{"rendered":"

[vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” rt_padding_bottom=”0″][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_empty_space height=”180px” el_class=”keno”][vc_column_text]<\/p>\n\n\n\n
\n
Oncology<\/div>\n

 <\/p>\n

Haematology<\/div>\n<\/td>\n
\n
Haematological malignancies (blood cancers) are the fifth most common cancer group in economically developed regions of the world. Traditionally, they are categorised by site according to whether cancer is first detected in the blood (leukaemias), lymph nodes (lymphomas – Hodgkin and non-Hodgkin) or bone (myelomas).1<\/sup><\/div>\n

 <\/p>\n

\n

Solid tumors make up the majority of malignancies2,3<\/sup>. They are mainly classified as carcinomas and sarcomas based on the type of cells they originate from. Solid tumors include common malignancies such as breast cancer, lung cancer and prostate cancer.<\/p>\n

    \n
  1. https:\/\/hmrn.org\/about\/classification<\/li>\n
  2. https:\/\/gco.iarc.fr\/today<\/li>\n
  3. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2019\/cancer-facts-and-figures-2019.pdf<\/li>\n<\/ol>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    [\/vc_column_text][vc_column_text]<\/p>\n\n\n\n\n
    \n
    Oncology<\/div>\n

     <\/p>\n

    Haematology<\/div>\n<\/td>\n<\/tr>\n
    <\/td>\n\n
    Haematological malignancies (blood cancers) are the fifth most common cancer group in economically developed regions of the world. Traditionally, they are categorised by site according to whether cancer is first detected in the blood (leukaemias), lymph nodes (lymphomas – Hodgkin and non-Hodgkin) or bone (myelomas).1<\/sup><\/div>\n

     <\/p>\n

    \n

    Solid tumors make up the majority of malignancies2,3<\/sup>. They are mainly classified as carcinomas and sarcomas based on the type of cells they originate from. Solid tumors include common malignancies such as breast cancer, lung cancer and prostate cancer.<\/p>\n

      \n
    1. https:\/\/hmrn.org\/about\/classification<\/li>\n
    2. https:\/\/gco.iarc.fr\/today<\/li>\n
    3. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2019\/cancer-facts-and-figures-2019.pdf<\/li>\n<\/ol>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”fullwidth” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” rt_padding_left=”0″ rt_padding_right=”0″ class=”etairia_tetragono_me_keimeno”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_padding_left=”0″ rt_padding_right=”0″][vc_raw_html el_class=”ogko_aim”]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[\/vc_raw_html][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]<\/p>\n\n\n\n\n
      Advanced \/ Metastatic<\/span><\/td>\n<\/tr>\n
      \"\"<\/td>\n\n
      Breast Cancer<\/strong><\/div>\n

       <\/p>\n

      \n

      Breast cancer is the most common malignancy in women1<\/sup>.<\/p>\n

      In 2020, the estimated incidence was 355,457 cases in EU-27 and 7,772 cases in Greece2<\/sup>.<\/p>\n

      Approximately 1 in 11 women in the EU-27 will develop breast cancer before the age of 742<\/sup>.<\/p>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nRead More<\/a><\/span>\n

      \n
      \n

      Some of the most important risk factors are gender, age, genetic factors (BRCA), estrogen exposure, radiation, number of pregnancies, increased breast density and atypical hyperplasia3<\/sup>. Other lifestyle factors such as alcohol consumption, body weight, diet and exercise are likely to impact the potential risk3,4<\/sup>.<\/p>\n

      Tumors are categorized based on histology and routine immunohistochemistry to better define the benefit from various treatments as well as prognosis. Key parameters examined are the histological type, the degree of differentiation, the expression of hormone receptors (ER, PR), the status of the HER2 receptor, the Ki67 index as well as the molecular signature3,4<\/sup>.<\/p>\n

      Treatment options include local treatment (surgery and radiotherapy) as well as systemic treatment (hormone therapy, chemotherapy, anti-HER2 therapy, targeted therapies and immunotherapies)3,4,5<\/sup>.<\/p>\n

      At the time of diagnosis, approximately 5-10% of tumors are metastatic, that is, the malignancy has spread from the primary site (the breast) to other parts of the body6<\/sup>.<\/p>\n

      Sources<\/span><\/p>\n

        \n
      1. ECIS-European Cancer Information System. https:\/\/ecis.jrc.ec.europa.eu\/ , last accessed 3\/7\/2023.<\/li>\n
      2. Europa Donna Breast cancer facts. https:\/\/www.europadonna.org\/breast-cancer\/ ,last accessed 3\/7\/2023.<\/li>\n
      3. Cardoso F. et al. Early Breast Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220.<\/li>\n
      4. \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ac \u03c0\u03c1\u03c9\u03c4\u03cc\u03ba\u03bf\u03bb\u03bb\u03b1 \u0395\u039f\u03a0\u0395, 9\u03b7 \u03ad\u03ba\u03b4\u03bf\u03c3\u03b7. https:\/\/www.hesmo.gr\/images\/%CE%98%CE%B5%CF%81%CE%B1%CF%80%CE%B5%CF%85%CF%84%CE%B9%CE%BA%CE%AC_%CE%A0%CF%81%CF%89%CF%84%CF%8C%CE%BA%CE%BF%CE%BB%CE%BB%CE%B1_%CE%95%CE%9F%CE%A0%CE%95-9%CE%B7_%CE%88%CE%BA%CE%B4%CE%BF%CF%83%CE%B7_final_1.pdf ,last accessed 3\/7\/2023.<\/li>\n
      5. Gennari A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 2021 Dec;32(12):1475-1495.<\/li>\n
      6. Europa Donna statistics\/guidelines. https:\/\/www.europadonna.org\/metastatic\/statistics-guidelines\/ ,last accessed 6\/7\/2023.<\/li>\n<\/ol>\n<\/div>\n

        <\/div>[\/vc_column_text][vc_column_text]<\/p>\n\n\n\n\n\n
        \"\"<\/td>\n<\/tr>\n
        Advanced \/ Metastatic<\/td>\n<\/tr>\n
        <\/td>\n\n
        Breast Cancer<\/strong><\/div>\n

         <\/p>\n

        \n

        Breast cancer is the most common malignancy in women1<\/sup>.<\/p>\n

        In 2020, the estimated incidence was 355,457 cases in EU-27 and 7,772 cases in Greece2<\/sup>.<\/p>\n

        Approximately 1 in 11 women in the EU-27 will develop breast cancer before the age of 742<\/sup>.<\/p>\nRead More<\/a><\/span>\n


        \nSome of the most important risk factors are gender, age, genetic factors (BRCA), estrogen exposure, radiation, number of pregnancies, increased breast density and atypical hyperplasia3<\/sup>. Other lifestyle factors such as alcohol consumption, body weight, diet and exercise are likely to impact the potential risk3,4<\/sup>.<\/p>\n

        Tumors are categorized based on histology and routine immunohistochemistry to better define the benefit from various treatments as well as prognosis. Key parameters examined are the histological type, the degree of differentiation, the expression of hormone receptors (ER, PR), the status of the HER2 receptor, the Ki67 index as well as the molecular signature3,4<\/sup>.<\/p>\n

        Treatment options include local treatment (surgery and radiotherapy) as well as systemic treatment (hormone therapy, chemotherapy, anti-HER2 therapy, targeted therapies and immunotherapies)3,4,5<\/sup>.<\/p>\n

        At the time of diagnosis, approximately 5-10% of tumors are metastatic, that is, the malignancy has spread from the primary site (the breast) to other parts of the body6<\/sup>.<\/p>\n

        Sources<\/span><\/p>\n

          \n
        1. ECIS-European Cancer Information System. https:\/\/ecis.jrc.ec.europa.eu\/ , last accessed 3\/7\/2023.<\/li>\n
        2. Europa Donna Breast cancer facts. https:\/\/www.europadonna.org\/breast-cancer\/ ,last accessed 3\/7\/2023.<\/li>\n
        3. Cardoso F. et al. Early Breast Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220.<\/li>\n
        4. \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ac \u03c0\u03c1\u03c9\u03c4\u03cc\u03ba\u03bf\u03bb\u03bb\u03b1 \u0395\u039f\u03a0\u0395, 9\u03b7 \u03ad\u03ba\u03b4\u03bf\u03c3\u03b7. https:\/\/www.hesmo.gr\/images\/%CE%98%CE%B5%CF%81%CE%B1%CF%80%CE%B5%CF%85%CF%84%CE%B9%CE%BA%CE%AC_%CE%A0%CF%81%CF%89%CF%84%CF%8C%CE%BA%CE%BF%CE%BB%CE%BB%CE%B1_%CE%95%CE%9F%CE%A0%CE%95-9%CE%B7_%CE%88%CE%BA%CE%B4%CE%BF%CF%83%CE%B7_final_1.pdf ,last accessed 3\/7\/2023.<\/li>\n
        5. Gennari A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 2021 Dec;32(12):1475-1495.<\/li>\n
        6. Europa Donna statistics\/guidelines. https:\/\/www.europadonna.org\/metastatic\/statistics-guidelines\/ ,last accessed 6\/7\/2023.<\/li>\n<\/ol>\n

          <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

          [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]<\/p>\n\n\n\n\n
          Multiple<\/td>\n<\/tr>\n
          <\/td>\n\n
          myeloma<\/strong><\/div>\n

           <\/p>\n

          \n

          Multiple myeloma is a neoplastic disease of plasma cells, a type of white blood cell that normally produces antibodies1<\/sup>.<\/p>\n

          Multiple myeloma accounts for 1%-1.8% of all malignancies2<\/sup> and 10% of all hematological malignancies1<\/sup>.<\/p>\nRead More<\/a><\/span>\n


          \nThe prevalence in Europe is 4.5 – 6.0 cases per 100,000 people per year2<\/sup> and the average age of the disease onset is between 65-74 years3<\/sup>.<\/p>\n

          At the time of diagnosis, most patients with multiple myeloma present with symptoms, signs, and laboratory findings of active disease such as painful osteolytic lesions (bone pain, back pain, fractures), hypercalcemia, anemia, and renal failure1<\/sup>.<\/p>\n

          The disease is divided into two types: relapsed and refractory multiple myeloma. Relapsed multiple myeloma is defined as relapsing when the disease recurs after treatment or a period of remission4<\/sup> and refractory when the disease does not improve or no longer responds to treatment5<\/sup>.<\/p>\n

          The causes of multiple myeloma are unknown6<\/sup>.<\/p>\n

          The question of why multiple myeloma develops remains largely unanswered to this day1<\/sup>.<\/p>\n

          Sources<\/span><\/p>\n

            \n
          1. http:\/\/myeloma.med.uoa.gr\/httpmyelomameduoagr\/ti-einai-to-pollaployn-myelwma.html<\/li>\n
          2. Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. Blood Cancer J. 2018;8:123<\/li>\n
          3. National Cancer Institute. Cancer stat facts: myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed January 2019<\/li>\n
          4. https:\/\/www.webmd.com\/cancer\/multiple-myeloma\/relapsed-multiple-myeloma , Accessed May 30th 2022<\/li>\n
          5. https:\/\/www.webmd.com\/cancer\/multiple-myeloma\/refractory-multiple-myeloma#:~:text=Getting%20Support-,What%20Is%20Refractory%20Multiple%20Myeloma%3F,it%20stops%20responding%20to%20treatment , Accessed May 30th, 2022<\/li>\n
          6. World cancer report p chapter 5.13)<\/li>\n<\/ol>\n

            <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

            [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_padding_left=”0″][vc_column_text]<\/p>\n\n\n\n\n
            Diffuse Large<\/td>\n<\/tr>\n
            <\/td>\n\n
            B-Cell Lymphoma<\/strong> (DLBCL)<\/div>\n

             <\/p>\n

            \n

            DLBCL is the most common type of high-grade non-Hodgkin lymphoma, with nearly half of all cases of high-grade non-Hodgkin lymphoma being DLBCL1<\/sup>.<\/p>\nRead More<\/a><\/span>\n


            \nNon-Hodgkin’s lymphoma (NHL) refers to a group of neoplasms of the lymphatic system with different characteristics, which originate from lymphocytes, a type of white blood cells involved in the body’s immune system2<\/sup>.<\/p>\n

            There are different subtypes of DLBCL, e.g. germinal center or activated B cell, while there are also some rare types of DLBCL1,3<\/sup>.<\/p>\n

            About half of patients diagnosed with DLBCL are over 60 years of age at the time of diagnosis3<\/sup>, but the disease can develop at any age1<\/sup>.<\/p>\n

            DLBCL is slightly more common in men1<\/sup>. The prevalence in Europe is 3-4 new patients per 100,000 population4<\/sup>.<\/p>\n

            Often, the first symptom of DLBCL is a painless, rapidly growing lump in the neck, armpit, or groin area, which is caused by an enlarged lymph node5<\/sup>.<\/p>\n

            Other symptoms may include night sweats, fever, unexplained weight loss, while patients may also notice fatigue, loss of appetite, shortness of breath, aches, itchy skin, persistent or recurring infections5,6<\/sup>.<\/p>\n

            Diagnosis can be difficult6<\/sup> and involves biopsy, blood tests and imaging tests5,6<\/sup>, the results of which determine the staging, grade and subtype of DLBCL5,6<\/sup>.<\/p>\n

            There are various treatments available for DLBCL, the choice of which will depend on many factors including DLBCL subtype, stage and grade of DLBCL, age, overall health, other treatments for either DLBCL or other diseases5<\/sup>.<\/p>\n

            DLBCL can be cured in almost half of patients7<\/sup>.<\/p>\n

            Sources<\/span><\/p>\n

              \n
            1. http:\/\/pathophysiology2.med.uoa.gr\/fileadmin\/pathophysiology.med.uoa.gr\/uploads\/RECONET-DIACHYTO_LEMFOMA_APO_MEGALA_B-KYTTARA_ELLINIKA.pdf<\/li>\n
            2. Leukemia & Lymphoma Society. NHL. http:\/\/www.lls.org\/lymphoma\/non-hodgkin-lymphoma?src1=20045&src2. Accessed 13 May 2022<\/li>\n
            3. Cancer.net. Lymphoma – Non-Hodgkin: Subtypes. http:\/\/www.cancer.net\/cancer-types\/lymphoma-non-hodgkin\/subtypes. Accessed 13 May 2022.<\/li>\n
            4. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018;50 (1):74\u201387.<\/li>\n
            5. Lymphoma Research Foundation. Understanding Diffuse Large B-Cell Lymphoma. LRF_Factsheet_Diffuse_Large_B_Cell_ Lymphoma.pdf. Accessed 13 May 2022<\/li>\n
            6. https:\/\/www.lymphoma.org.au\/el\/types-of-lymphoma\/non-hodgkin-lymphoma\/aggressive-fast-growing-b-cell-nhl\/
              \ndiffuse-large-b-cell-dlbcl\/<\/li>\n
            7. https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/treating\/b-cell-lymphoma.html<\/li>\n<\/ol>\n

              <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

              [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row” rt_padding_top=”0″][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]<\/p>\n\n\n\n\n
              Mantle cell<\/td>\n<\/tr>\n
              <\/td>\n\n
              lymphoma<\/strong><\/div>\n

               <\/p>\n

              \n

              Mantle cell lymphoma is a rare hematologic malignancy classified among non-Hodgkin lymphomas (NHL). It represents approximately 4% of all cancers and accounts for 3-10% of all NHL cases, making it an atypical form of NHL. The annual incidence is 0.5-1 new case per 100,000 population1<\/sup>.<\/p>\n

              Although the disease is more common in men over 60 years old, it can be diagnosed in women and individuals of all ages2<\/sup>.<\/p>\nRead More<\/a><\/span>\n


              \nThe disease may initially present mildly, but over time, it can progress into a more aggressive form2<\/sup>.<\/p>\n

              Upon diagnosis, patients typically exhibit lymphadenopathy, splenomegaly, gastrointestinal infiltration, and bone marrow involvement3<\/sup>.They may also experience non-specific symptoms such as fever, sweating, and weight loss.<\/p>\n

              Specific predisposing factors for the disease have not yet been identified4<\/sup>.<\/p>\n

              Diagnosis is based on medical history, physical examination, laboratory tests, lymph node biopsy and bone marrow biopsy5<\/sup>. A characteristic finding is the overexpression of cyclin D15<\/sup>.<\/p>\n

              Treatment includes pharmacological treatment and bone marrow transplantation6<\/sup>.<\/p>\n

              Despite recent advances, mantle cell lymphoma remains an incurable disease, and high-risk patients have a poor prognosis3<\/sup>.<\/p>\n

              Sources<\/span><\/p>\n

                \n
              1. Medscape. Mantle Cell Lymphoma https:\/\/emedicine.medscape.com\/article\/203085-overview#a4<\/li>\n
              2. Lymphoma Research Foundation 2022, factsheet https:\/\/lymphoma.org\/wp-content\/uploads\/2023\/04\/LRF_Mantle_Cell_Lymphoma_Factsheet.pdf<\/li>\n
              3. Schieber M, Gordon LI and Karmali R. Current overview and treatment of mantle cell lymphoma [version 1; peer review: 3 approved]. F1000Research 2018, 7(F1000 Faculty Rev):1136<\/li>\n
              4. Preetesh Jain, Michael Wang , Am J Hematol.2019;94:710\u2013725.<\/li>\n
              5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375- 2390<\/li>\n
              6. Eyre TA, Cheah CY, Wang ML. Blood. 2022 Feb 3;139(5):666-677. doi: 10.1182\/blood.2021013326<\/li>\n<\/ol>\n

                <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_padding_left=”0″ rt_padding_right=”0″][vc_column_text]<\/p>\n\n\n\n\n
                High risk<\/span><\/td>\n<\/tr>\n
                \"\"<\/td>\n\n
                Neuroblastoma<\/strong><\/div>\n

                 <\/p>\n

                Neuroblastoma is the most common extracranial solid tumor of childhood. In approximately 90% of cases, the diagnosis is made at an age younger than 5 years, with a median age of diagnosis at 17 months1<\/sup>.<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nRead More<\/a><\/span>\n
                \n
                \n

                This is a malignancy that primarily originates from neural tissue found in the adrenal glands, neck, thorax, and the spinal cord2<\/sup>.<\/p>\n

                Neuroblastomas are classified into very low risk\/low risk, intermediate risk, and high-risk categories, based on various factors such as age, histology, degree of differentiation, the number of MYCN copies3,1<\/sup>.<\/p>\n

                For the treatment of high-risk neuroblastomas, chemotherapy, surgery, bone marrow transplantation, radiation therapy, retinoids, and immunotherapy can be used4<\/sup>.<\/p>\n

                Sources<\/span><\/p>\n

                  \n
                1. Neuroblastoma Treatment (PDQ\u00ae)\u2013Health Professional Version. https:\/\/www.cancer.gov\/types\/neuroblastoma\/hp\/neuroblastoma-treatment-pdq ,last accessed 6\/7\/2023<\/li>\n
                2. SIOP Europe main types of paediatric cancers. https:\/\/siope.eu\/parents-and-patients\/general-information-on-clinicaltrials\/main-types-paediatric-cancer\/ ,last accessed 6\/7\/2023<\/li>\n
                3. Irwin MS. et al. Revised Neuroblastoma Risk Classification System: A Report From the Children\u2019s Oncology Group. J Clin Oncol. 2021 Oct 10;39(29):3229-3241.<\/li>\n
                4. Treatment by risk group for neuroblastoma. https:\/\/www.cancerresearchuk.org\/about-cancer\/childrens-cancer\/neuroblastoma\/treatment-risk-group ,last accessed 6\/7\/2023.<\/li>\n<\/ol>\n<\/div>\n

                  <\/div>
                  \n[\/vc_column_text][vc_column_text]<\/p>\n\n\n\n\n\n
                  \"\"<\/td>\n<\/tr>\n
                  High risk<\/td>\n<\/tr>\n
                  <\/td>\n\n
                  Neuroblastoma<\/strong><\/div>\n

                   <\/p>\n

                  \n

                  Neuroblastoma is the most common extracranial solid tumor of childhood. In approximately 90% of cases, the diagnosis is made at an age younger than 5 years, with a median age of diagnosis at 17 months1<\/sup>.<\/p>\nRead More<\/a><\/span>\n


                  \nThis is a malignancy that primarily originates from neural tissue found in the adrenal glands, neck, thorax, and the spinal cord2<\/sup>.<\/p>\n

                  Neuroblastomas are classified into very low risk\/low risk, intermediate risk, and high-risk categories, based on various factors such as age, histology, degree of differentiation, the number of MYCN copies3,1<\/sup>.<\/p>\n

                  For the treatment of high-risk neuroblastomas, chemotherapy, surgery, bone marrow transplantation, radiation therapy, retinoids, and immunotherapy can be used4<\/sup>.<\/p>\n

                  Sources<\/span><\/p>\n

                    \n
                  1. Neuroblastoma Treatment (PDQ\u00ae)\u2013Health Professional Version. https:\/\/www.cancer.gov\/types\/neuroblastoma\/hp\/neuroblastoma-treatment-pdq ,last accessed 6\/7\/2023<\/li>\n
                  2. SIOP Europe main types of paediatric cancers. https:\/\/siope.eu\/parents-and-patients\/general-information-on-clinicaltrials\/main-types-paediatric-cancer\/ ,last accessed 6\/7\/2023<\/li>\n
                  3. Irwin MS. et al. Revised Neuroblastoma Risk Classification System: A Report From the Children\u2019s Oncology Group. J Clin Oncol. 2021 Oct 10;39(29):3229-3241.<\/li>\n
                  4. Treatment by risk group for neuroblastoma. https:\/\/www.cancerresearchuk.org\/about-cancer\/childrens-cancer\/neuroblastoma\/treatment-risk-group ,last accessed 6\/7\/2023.<\/li>\n<\/ol>\n

                    <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                    [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row” rt_padding_top=”0″][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]<\/p>\n\n\n\n\n
                    Castleman’s<\/td>\n<\/tr>\n
                    <\/td>\n\n
                    Disease<\/strong><\/div>\n

                     <\/p>\n

                    \n

                    Castleman’s disease is a rare disorder that shares common lymph node histological features. There are two clinical entities described: unicentric, involving a single lymph node, and multicentric, characterized by generalized lymphadenopathy and a more aggressive clinical course1<\/sup>.<\/p>\n

                    Although the etiology of multicentric disease is unknown, interleukin-6 (IL-6) is a confirmed risk factor for the disease in approximately one-third of patients2<\/sup>.<\/p>\nRead More<\/a><\/span>\n


                    \nThe Castleman Disease Collaborative Network (CDCN) is investigating four hypotheses that could be linked to the etiology, including autoimmune, inflammatory, neoplastic, and pathogenetic mechanisms3,7<\/sup>.<\/p>\n

                    Human herpesvirus 8 (HHV8) causes multicentric Castleman’s disease in immunosuppressed patients, while in patients not affected by HHV8, the disease is considered idiopathic1,5<\/sup>.<\/p>\n

                    The epidemiology of multicentric Castleman’s disease has not been widely studied. Men appear to be affected more frequently than women. The average age of diagnosis is during the patient’s sixth decade of life, but the disease can occur at any age, even in young children11,14<\/sup>.<\/p>\n

                    The disease presents with different forms, with some patients having mild non-specific symptoms, while others may develop multi-organ failure or even a fatal outcome9,10<\/sup>.<\/p>\n

                    Diagnosis is based on clinical examination, biopsy, as well as laboratory and imaging tests16<\/sup>.
                    \nTreatment includes surgical intervention and\/or radiation therapy and pharmacological management16<\/sup>.<\/p>\n

                    Sources<\/span><\/p>\n

                      \n
                    1. Amel El Korbi et al. PAMJ – 37(369). 22 Dec 2020<\/li>\n
                    2. Sheila K. Pierson Blood Adv (2021) 5 (17): 3445\u20133456<\/li>\n
                    3. Fajgenbaum DC, van Rhee F , Nabel CS . HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy . Blood . 2014 ;123 (19 ):2924 -2933<\/li>\n
                    4. Yoshizaki K , Matsuda T , Nishimoto N , et al. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease . Blood . 1989 ;74 (4 ):1360 -1367<\/li>\n
                    5. Nishimoto N , Terao K , Mima T , Nakahara H , Takagi N , Kakehi T . Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease . Blood . 2008 ;112 (10 ):3959 -3964<\/li>\n
                    6. Stone K , Woods E , Szmania SM , et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels . PLoS One . 2013 ;8 (1 ):e54610<\/li>\n
                    7. Fajgenbaum DC , Ruth JR , Kelleher D , Rubenstein AH . The collaborative network approach: a new framework to accelerate Castleman\u2019s disease and other rare disease research . Lancet Haematol . 2016 ;3 (4 ):e150 -e152<\/li>\n
                    8. Iwaki N , Sato Y , Takata K , et al. Atypical hyaline vascular-type castleman\u2019s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy . J Clin Exp Hematop . 2013 ;53 (1):87-93<\/li>\n
                    9. Iwaki N Fajgenbaum DC , Nabel CS , et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease Am J Hematol. 2016 ;91 (2):220-226<\/li>\n
                    10. Kawabata H , Kotani S , Matsumura Y , et al. Successful treatment of a patient with multicentric Castleman\u2019s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody . Intern Med. 2013 ;52 (13):1503-1507<\/li>\n
                    11. Frizzera G, Banks PM , Massarelli G , Rosai J . A systemic lymphoproliferative disorder with morphologic features of Castleman\u2019s disease. Pathological findings in 15 patients Am J Surg Pathol. 1983 ;7 (3):211 -231<\/li>\n
                    12. Bowne WB , Lewis JJ , Filippa DA , et al. The management of unicentric and multicentric Castleman\u2019s disease: a report of 16 cases and a review of the literature . Cancer . 1999 ;85 (3):706-717<\/li>\n
                    13. Chronowski GM , Ha CS , Wilder RB , Cabanillas F , Manning J, Cox JD .Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001 ;92 (3):670-676<\/li>\n
                    14. Parez N , Bader-Meunier B , Roy CC, Dommergues JP. Paediatric Castleman disease: report of seven cases and review of the literature. Eur J Pediatr. 1999;158 (8):631-637<\/li>\n
                    15. https:\/\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026(16)00006-5\/fulltext<\/li>\n
                    16. Dispenzieri A, Fajgenbaum DC Blood (2020) 135 (16): 1353\u20131364.<\/li>\n<\/ol>\n

                      <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                      [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row” rt_padding_top=”0″][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]<\/p>\n\n\n\n\n
                      Blastic Plasmacytoid<\/td>\n<\/tr>\n
                      <\/td>\n\n
                      Dendritic<\/strong>
                      \nCell Neoplasm (BPDCN)<\/div>\n

                       <\/p>\n

                      \n

                      BPDCN is a rare hematological cancer that belongs to the category of acute myeloid leukemias and related neoplasms1<\/sup>. It represents 0.44% of new hematological malignancies each year, which means a prevalence of 0.04 new patients per 100,000 population, thus approximately 700 new patients in the United States and about 1,000 new patients in Europe2<\/sup>.<\/p>\nRead More<\/a><\/span>\n


                      \nBPDCN more commonly affects patients over the age of 60, but cases have been recorded in young individuals under the age of 20, as well as in children.2,3,4,5<\/sup>.
                      \nThe etiology of BPDCN is not known. Recent studies have shown that the neoplasm initially appears in the skin and subsequently disseminates to the bone marrow. Both at diagnosis and during the course of the disease’s flares and remissions, continuous genetic mutations are detected in the skin or bone marrow.3,6-9<\/sup>.
                      \nDermatologists are usually the first to come in contact with BPDCN patients, as skin lesions are the hallmark of the disease. The lesions are heterogeneous and may be isolated or widespread, scattered over a wide range10-14<\/sup>.
                      \nThe diagnosis of BPDCN is primarily based on the immunophenotype of leukemic cells in samples from the skin, blood, and bone marrow15<\/sup>.<\/p>\n

                      The prognosis for the disease is poor2<\/sup>.<\/p>\n

                        \n
                      1. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391\u20132405.<\/li>\n
                      2. Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 2018;73: 21\u20133.<\/li>\n
                      3. Venugopal S, Zhou S, El Jamal SM et al. Blastic plasmacytoid dendritic cell neoplasm \u2013 current insights. Clin Lymphoma Myeloma Leuk 2019;19:545\u201354.<\/li>\n
                      4. Jegalian AG, Buxbaum P, Facchetti F et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica 2010;95:1873\u20139.<\/li>\n
                      5. Li Y, Sun V, Sun W, Pawlowska A. Blastic plasmacytoid dendritic cell neoplasm in children. Hematol Oncol Clin North Am 2020;34:601\u201312.<\/li>\n
                      6. Sakamoto K, Takeuchi K. Cytogenetics of blastic plasmacytoid dendritic cell neoplasm: chromosomal rearrangements and DNA copynumber alterations. Hematol Oncol Clin North Am 2020;34:523\u201338.<\/li>\n
                      7. Laribi K, Denizon N, Ghnay H et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol 2014;93:81\u20135.<\/li>\n
                      8. Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control 2014;21:279\u201389.<\/li>\n
                      9. Sapienza MR, Pileri S. Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics. Hematol Oncol Clin North Am 2020;34:511\u201321.<\/li>\n
                      10. Hirner JP, O\u2019Malley JT, LeBoeuf NR. Blastic plasmacytoid dendritic cell neoplasm: the dermatologist\u2019s perspective. Hematol Oncol Clin North Am 2020;34:501\u20139.<\/li>\n
                      11. Garnache-Ottou F, Vidal C, Biichl\u00e9 S et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv 2019;3:4238\u201351.<\/li>\n
                      12. Deconinck E, Petrella T, Garnache Ottou F. Blastic plasmacytoid dendritic cell neoplasm: clinical presentation and diagnosis. Hematol Oncol Clin North Am 2020;34: 491\u2013500.<\/li>\n
                      13. Julia F, Dalle S, Duru G et al. Blastic plasmacytoid dendritic cell neoplasms: clinicoimmunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 2014;38:673\u201380.<\/li>\n
                      14. ulia F, Petrella T, Beylot-Barry M et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 2013;169: 579\u201386.<\/li>\n
                      15. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188\u2013202<\/li>\n<\/ol>\n

                        <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                        [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_padding_left=”0″ rt_padding_right=”0″][vc_column_text]<\/p>\n\n\n\n\n
                        Ototoxicity<\/strong><\/span><\/td>\n<\/tr>\n
                        \"\"<\/td>\n\n
                        in Oncology Patients<\/div>\n

                         <\/p>\n

                        \n

                        Cisplatin is a fundamental therapeutic agent for the treatment of various pediatric solid malignancies, leading to increased survival in these patient1<\/sup>.<\/p>\n

                        This therapeutic agent can lead to ototoxicity, which may manifest as hearing loss, ringing in the ears (tinnitus), and\/or dizziness2<\/sup>.<\/p>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nRead More<\/a><\/span>\n

                        \n
                        \n

                        Cisplatin-induced ototoxicity results from the destruction of the hair cells in the cochlea and initially affects high frequencies. It is typically bilateral, irreversible and progressive2<\/sup>.<\/p>\n

                        There are international recommendations that suggest assessing auditory function based on age and risk factors, using hearing tests such as pure-tone audiometry, auditory brainstem response (ABR) testing, and otoacoustic emissions3<\/sup>.<\/p>\n

                        Sources<\/span><\/p>\n

                          \n
                        1. Chattarah A. et al. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO Oncol. Pract. 2023;19(5):278-283<\/li>\n
                        2. Landier W. et al. Ototoxicity and Cancer therapy. Cancer 2016;122(11):1647-1658.<\/li>\n
                        3. Meijer J. M. et al. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncol 2021;7(10):1550-1558.doi:10.1001\/jamaoncol.2021.2697.<\/li>\n<\/ol>\n<\/div>\n

                          <\/div>
                          \n[\/vc_column_text][vc_column_text]<\/p>\n\n\n\n\n\n
                          \"\"<\/td>\n<\/tr>\n
                          Ototoxicity<\/strong><\/td>\n<\/tr>\n
                          <\/td>\n\n
                          in Oncology
                          \nPatients<\/div>\n

                           <\/p>\n

                          \n

                          Cisplatin is a fundamental therapeutic agent for the treatment of various pediatric solid malignancies, leading to increased survival in these patients1<\/sup>.<\/p>\n

                          This therapeutic agent can lead to ototoxicity, which may manifest as hearing loss, ringing in the ears (tinnitus), and\/or dizziness2<\/sup>.<\/p>\nRead More<\/a><\/span>\n


                          \nCisplatin-induced ototoxicity results from the destruction of the hair cells in the cochlea and initially affects high frequencies. It is typically bilateral, irreversible and progressive2<\/sup>.<\/p>\n

                          There are international recommendations that suggest assessing auditory function based on age and risk factors, using hearing tests such as pure-tone audiometry, auditory brainstem response (ABR) testing, and otoacoustic emissions3<\/sup>.<\/p>\n

                          Sources<\/span><\/p>\n

                            \n
                          1. Chattarah A. et al. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO Oncol. Pract. 2023;19(5):278-283<\/li>\n
                          2. Landier W. et al. Ototoxicity and Cancer therapy. Cancer 2016;122(11):1647-1658.<\/li>\n
                          3. Meijer J. M. et al. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncol 2021;7(10):1550-1558.doi:10.1001\/jamaoncol.2021.2697.<\/li>\n<\/ol>\n

                            <\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                            [\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” class=”small_row”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]This information is intended for public awareness purposes only and, under no circumstances, can it replace the advice of a doctor or another qualified healthcare professional.<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted”][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_raw_html]JTNDZGl2JTIwY2xhc3MlM0QlMjJtMTNfaW4lMjIlM0VUaGVyYXBldXRpYyUwQSUzQ2RpdiUyMGNsYXNzJTNEJTIybWVzYV9pbiUyMiUzRUFyZWFzJTNDJTJGZGl2JTNFJTNDJTJGZGl2JTNF[\/vc_raw_html][\/vc_column][\/vc_row][vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” rt_padding_top=”0″ rt_padding_left=”0″ rt_padding_right=”0″ rt_padding_bottom=”0″][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_column_text]<\/p>\n\n\n\n\n
                            \"\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
                             <\/p>\n
                            Oncology | Hematology<\/div>\n

                             <\/td>\n

                            		 <\/p>\n
                            Rare and Genetic
                            \nMetabolic Diseases<\/div>\n

                             <\/td>\n

                            		 <\/p>\n
                            Wound\u00a0Care<\/div>\n

                             <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                            [\/vc_column_text][vc_column_text]<\/p>\n

                            \n

                            \"\"<\/p>\n

                            Oncology<\/div>\n

                             <\/p>\n

                            \n

                            Hematology<\/span><\/p>\n

                            <\/div>\n<\/div>\n

                             <\/p>\n

                            Read more<\/a><\/div>\n

                             <\/p>\n<\/div>\n

                            \n

                            \"\"<\/p>\n

                            Rare and Genetic
                            \nMetabolic Diseases<\/div>\n

                             <\/p>\n

                            \n
                            <\/div>\n<\/div>\n

                             <\/p>\n

                            Read more<\/a><\/div>\n

                             <\/p>\n<\/div>\n

                            \n

                            \"\"<\/p>\n

                            Wound<\/div>\n

                             <\/p>\n

                            \n

                            Care<\/p>\n

                            <\/div>\n<\/div>\n

                             <\/p>\n

                            Read more<\/a><\/div>\n

                             <\/p>\n<\/div>\n

                            [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

                            [vc_row rt_row_background_width=”fullwidth” rt_row_content_width=”default” rt_row_style=”default-style” rt_row_borders=”” rt_row_paddings=”true” rt_bg_effect=”classic” rt_bg_image_repeat=”repeat” rt_bg_size=”cover” rt_bg_position=”right top” rt_bg_attachment=”scroll” rt_bg_video_format=”self-hosted” rt_padding_bottom=”0″][vc_column rt_wrp_col_paddings=”false” rt_border_top=”” rt_border_bottom=”” rt_border_left=”” rt_border_right=”” rt_border_top_mobile=”” rt_border_bottom_mobile=”” rt_border_left_mobile=”” rt_border_right_mobile=”” rt_bg_image_repeat=”repeat” rt_bg_size=”auto auto” rt_bg_position=”right top” rt_bg_attachment=”scroll”][vc_empty_space height=”180px” el_class=”keno”][vc_column_text] Oncology   Haematology Haematological malignancies (blood cancers) are the fifth most common cancer group in economically developed regions of the world. Traditionally, they are […]<\/p>\n","protected":false},"author":1,"featured_media":2005,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2049","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nINTEGRIS Pharma | \u039f\u03b3\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/title>\n<meta name=\"description\" content=\"\u039f\u03b9 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2 (\u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03b9 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03c0\u03b9\u03bf \u03c3\u03c5\u03c7\u03bd\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b9\u03ba\u03bf\u03bd\u03bf\u03bc\u03b9\u03ba\u03ac \u03b1\u03bd\u03b5\u03c0\u03c4\u03c5\u03b3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bf\u03c7\u03ad\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03cc\u03c3\u03bc\u03bf\u03c5.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INTEGRIS Pharma | \u039f\u03b3\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\" \/>\n<meta property=\"og:description\" content=\"\u039f\u03b9 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2 (\u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03b9 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03c0\u03b9\u03bf \u03c3\u03c5\u03c7\u03bd\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b9\u03ba\u03bf\u03bd\u03bf\u03bc\u03b9\u03ba\u03ac \u03b1\u03bd\u03b5\u03c0\u03c4\u03c5\u03b3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bf\u03c7\u03ad\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03cc\u03c3\u03bc\u03bf\u03c5.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/\" \/>\n<meta property=\"og:site_name\" content=\"Integirs Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-14T08:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"24 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/\",\"url\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/\",\"name\":\"INTEGRIS Pharma | \u039f\u03b3\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\",\"isPartOf\":{\"@id\":\"https:\/\/integris.gr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg\",\"datePublished\":\"2023-06-19T08:54:27+00:00\",\"dateModified\":\"2026-01-14T08:58:00+00:00\",\"description\":\"\u039f\u03b9 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2 (\u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03b9 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03c0\u03b9\u03bf \u03c3\u03c5\u03c7\u03bd\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b9\u03ba\u03bf\u03bd\u03bf\u03bc\u03b9\u03ba\u03ac \u03b1\u03bd\u03b5\u03c0\u03c4\u03c5\u03b3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bf\u03c7\u03ad\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03cc\u03c3\u03bc\u03bf\u03c5.\",\"breadcrumb\":{\"@id\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#primaryimage\",\"url\":\"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg\",\"contentUrl\":\"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/integris.gr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncology – Haematology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/integris.gr\/#website\",\"url\":\"https:\/\/integris.gr\/\",\"name\":\"INTEGRIS Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/integris.gr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/integris.gr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/integris.gr\/#organization\",\"name\":\"INTEGRIS Pharma\",\"url\":\"https:\/\/integris.gr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/integris.gr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-home.jpg\",\"contentUrl\":\"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-home.jpg\",\"width\":1200,\"height\":630,\"caption\":\"INTEGRIS Pharma\"},\"image\":{\"@id\":\"https:\/\/integris.gr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INTEGRIS Pharma | \u039f\u03b3\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03af\u03b1","description":"\u039f\u03b9 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2 (\u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03b9 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03c0\u03b9\u03bf \u03c3\u03c5\u03c7\u03bd\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b9\u03ba\u03bf\u03bd\u03bf\u03bc\u03b9\u03ba\u03ac \u03b1\u03bd\u03b5\u03c0\u03c4\u03c5\u03b3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bf\u03c7\u03ad\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03cc\u03c3\u03bc\u03bf\u03c5.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/","og_locale":"en_US","og_type":"article","og_title":"INTEGRIS Pharma | \u039f\u03b3\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03af\u03b1","og_description":"\u039f\u03b9 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2 (\u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03b9 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03c0\u03b9\u03bf \u03c3\u03c5\u03c7\u03bd\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b9\u03ba\u03bf\u03bd\u03bf\u03bc\u03b9\u03ba\u03ac \u03b1\u03bd\u03b5\u03c0\u03c4\u03c5\u03b3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bf\u03c7\u03ad\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03cc\u03c3\u03bc\u03bf\u03c5.","og_url":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/","og_site_name":"Integirs Pharma","article_modified_time":"2026-01-14T08:58:00+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"24 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/","url":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/","name":"INTEGRIS Pharma | \u039f\u03b3\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03af\u03b1","isPartOf":{"@id":"https:\/\/integris.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#primaryimage"},"image":{"@id":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#primaryimage"},"thumbnailUrl":"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg","datePublished":"2023-06-19T08:54:27+00:00","dateModified":"2026-01-14T08:58:00+00:00","description":"\u039f\u03b9 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2 (\u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03b9 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u03c0\u03ad\u03bc\u03c0\u03c4\u03b7 \u03c0\u03b9\u03bf \u03c3\u03c5\u03c7\u03bd\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b9\u03ba\u03bf\u03bd\u03bf\u03bc\u03b9\u03ba\u03ac \u03b1\u03bd\u03b5\u03c0\u03c4\u03c5\u03b3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bf\u03c7\u03ad\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03cc\u03c3\u03bc\u03bf\u03c5.","breadcrumb":{"@id":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/integris.gr\/en\/ogkologia-aimatologia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#primaryimage","url":"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg","contentUrl":"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-ogkologia-aimatologia.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/integris.gr\/en\/ogkologia-aimatologia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/integris.gr\/en\/"},{"@type":"ListItem","position":2,"name":"Oncology – Haematology"}]},{"@type":"WebSite","@id":"https:\/\/integris.gr\/#website","url":"https:\/\/integris.gr\/","name":"INTEGRIS Pharma","description":"","publisher":{"@id":"https:\/\/integris.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/integris.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/integris.gr\/#organization","name":"INTEGRIS Pharma","url":"https:\/\/integris.gr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integris.gr\/#\/schema\/logo\/image\/","url":"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-home.jpg","contentUrl":"https:\/\/integris.gr\/wp-content\/uploads\/2023\/10\/Integris-home.jpg","width":1200,"height":630,"caption":"INTEGRIS Pharma"},"image":{"@id":"https:\/\/integris.gr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/pages\/2049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/comments?post=2049"}],"version-history":[{"count":17,"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/pages\/2049\/revisions"}],"predecessor-version":[{"id":2815,"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/pages\/2049\/revisions\/2815"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/media\/2005"}],"wp:attachment":[{"href":"https:\/\/integris.gr\/en\/wp-json\/wp\/v2\/media?parent=2049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}